These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38313214)

  • 1. The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases.
    Zhou J; Zhou Y; Sun Y; Xiao L; Lu H; Yin X; Fan K
    Front Oncol; 2023; 13():1259880. PubMed ID: 38313214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases.
    Yu F; Ni J; Zeng W; Zhou Y; Guo T; Zeng Y; Zhao Y; Li S; Li Y; Yang X; Zou L; Wang S; Liu Q; Li Y; Chu L; Chu X; Ye L; Yu W; Zhu Z
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):804-815. PubMed ID: 34058255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Guo T; Chu L; Chu X; Yang X; Li Y; Zhou Y; Xu D; Zhang J; Wang S; Hu J; Chu Q; Moran T; Cho WC; Merrell KW; Rizzo S; Liu Y; Ni J; Zhu Z
    Transl Lung Cancer Res; 2022 Feb; 11(2):173-187. PubMed ID: 35280308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases.
    Wang Y; Wu S; Li J; Liang X; Zhou X
    Brain Sci; 2023 Sep; 13(9):. PubMed ID: 37759881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
    Qian J; He Z; Wu Y; Li H; Zhang Q; Li X
    BMC Cancer; 2024 Jan; 24(1):117. PubMed ID: 38262977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.
    Du XJ; Pan SM; Lai SZ; Xu XN; Deng ML; Wang XH; Yao DC; Wu SX
    Front Oncol; 2018; 8():603. PubMed ID: 30619745
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
    Niu L; Wu H; Gao R; Chen L; Wang J; Duan H; Long Y; Xie Y; Zhou Q; Zhou R
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):94. PubMed ID: 38369644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases.
    Dong K; Liang W; Zhao S; Guo M; He Q; Li C; Song H; He J; Xia X
    Transl Lung Cancer Res; 2019 Jun; 8(3):268-279. PubMed ID: 31367540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis.
    Zhao Y; Li S; Yang X; Chu L; Wang S; Tong T; Chu X; Yu F; Zeng Y; Guo T; Zhou Y; Zou L; Li Y; Ni J; Zhu Z
    Int J Cancer; 2022 Apr; 150(8):1318-1328. PubMed ID: 34914096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
    Miyawaki E; Kenmotsu H; Mori K; Harada H; Mitsuya K; Mamesaya N; Kawamura T; Kobayashi H; Nakashima K; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Endo M; Nakasu Y; Gon Y; Takahashi T
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):604-613. PubMed ID: 30851347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    Song Y; Lin S; Chen J; Dang J
    BMC Cancer; 2023 Oct; 23(1):1043. PubMed ID: 37904083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    Chen Y; Wei J; Cai J; Liu A
    BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant.
    Zhao L; Cai X; Chen D; Ye X; Gao M; Lu L; Su H; Su M; Hou M; Xie C
    Radiat Oncol; 2019 Dec; 15(1):3. PubMed ID: 31892337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical research on stereotactic radiosurgery combined with epithermal growth factor tyrosine kinase inhibitors in the treatment of brain metastasis of non-small cell lung cancer.
    Jia F; Cheng X; Zeng H; Miao J; Hou M
    J BUON; 2019; 24(2):578-584. PubMed ID: 31128009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
    Wang W; Song Z; Zhang Y
    Arch Med Sci; 2018 Oct; 14(6):1298-1307. PubMed ID: 30393484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing of hypofractionated stereotactic radiotherapy for epidermal growth factor receptor-mutated non-small-cell lung cancer patients with brain metastases.
    Liang S; Liu X; Liu J; Na F; Lai J; Du L; Gong Y; Zhu J; Huang M; Zhou X; Xu Y; Zhou L
    Asia Pac J Clin Oncol; 2023 Dec; 19(6):731-738. PubMed ID: 37088960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.
    Magnuson WJ; Yeung JT; Guillod PD; Gettinger SN; Yu JB; Chiang VL
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):673-9. PubMed ID: 27034176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases.
    Saida Y; Watanabe S; Abe T; Shoji S; Nozaki K; Ichikawa K; Kondo R; Koyama K; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Tsukada H; Makino M; Iwashima A; Sato K; Matsumoto N; Yoshizawa H; Kikuchi T
    Thorac Cancer; 2019 Nov; 10(11):2106-2116. PubMed ID: 31507098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.